9 ANNEX IX COMMON SPECIFICATIONS FOR DEVICES INTENDED FOR DETECTION OR QUANTIFICATION OF MARKERS OF CYTOMEGALOVIRUS (CMV) INFECTION, Regulation (EU) 2022/1107

In forcesince 4 Jul 2022

This Annex applies to devices intended for detection or quantification of markers of cytomegalovirus (CMV) infection.

Table 1 applies to first-line assays for total antibodies against CMV (total anti-CMV) and IgG antibodies against CMV (anti-CMV IgG).

Table 2 applies to qualitative and quantitative NAT devices for CMV DNA.

[Including testing of other CMV parameters (e.g. CMV-IgM, avidity, immunoblot) or previous / follow-up specimens to assess true specimen status.] [Supplementary testing to confirm recent CMV infection (primary or re-infection): e.g. CMV-IgM, IgG-avidity, immunoblot analysis.] [Corresponding to an initial number of 1000 donors at an assumed CMV prevalence of 60 %.] [Including pre-transplant recipients.] [Including related β-herpes viruses (HHV-6, HHV-7).]

Performance characteristic | Specimens | Specimen number, features, use | Acceptance criteria

Diagnostic sensitivity | Positive specimens |

≥400

including specimens from recent and past CMV infection,

low and high positive titre specimens

≥ 99% sensitivity for confirmable past infection;

overall sensitivity including recent infection shall be at least equivalent to the comparator device

Seroconversion panels | To be tested when available | Diagnostic sensitivity during seroconversion shall represent the state of the art

Analytical sensitivity | Standards |

WHO International Standard anti-CMV IgG (PEI-code 136616/17)

In case of titre determinations and quantitative statements

Diagnostic specificity | Negative specimens | ≥400 CMV negative specimens from unselected donors, as compared to another CMV test. | ≥ 99%

Hospitalised patients | ≥200 | Potential limitations for specificity, if any, shall be identified

Cross-reactivity | Potentially cross-reacting specimens |

≥100 in total

(e.g. RF+, related viruses or other infectious agents, pregnant women, etc.)

1.

For target sequence amplification devices, a functionality control for each specimen (internal control) shall reflect the state of the art. This control shall as far as possible be used throughout the whole process, i.e. extraction, amplification/hybridisation, detection.

2.

Genotype and/or subtype detection shall be demonstrated by appropriate primer or probe design validation and shall also be validated by testing characterised genotyped specimens.

3.

Potential cross-reactivity of non-target nucleic acid sequences shall be analysed by appropriate primer or probe design validation and shall also be validated by testing selected specimens.

4.

Results of quantitative NAT devices shall be traceable to international standards or calibrated reference materials, if available, and be expressed in international units utilised in the specific field of application.

[Reference: European Pharmacopeia 9.0, 2.6.21 Nucleic acid amplification techniques, Validation.]

Performance characteristic | Specimens | Specimen numbers, features, use | Acceptance criteria

Analytical sensitivity | WHO First International Standard Human CMV DNA (09/162; 5000000 IU/vial) (or calibrated reference materials) |

NAT sensitivity and NAT LOD shall be validated by dilution series of reference materials, testing of replicates (minimum 24) at different analyte concentrations, including those with transition from positive to negative results with the respective NAT device.

LOD shall be expressed as 95% positive cut-off value (IU/ml) after statistical analysis (e.g. Probit).

quantitative NAT: definition of lower, upper quantification limit, precision, accuracy,

‘linear’ measuring range, ‘dynamic range’.

Reproducibility at different concentration levels

According to the state of the art

Diagnostic sensitivity

CMV Strain sensitivity

Patient specimens determined as CMV DNA positive by comparator device

Dilution series of CMV positive cell cultures may serve as potential substitutes

Qualitative NAT: ≥100

Quantitative NAT: ≥100

dilution series for demonstration of quantification efficiencies

According to the state of the art

Diagnostic specificity | Blood donor specimens |

Qualitative NAT: ≥500

Quantitative NAT: ≥100

According to the state of the art

Cross-reactivity | Potentially cross-reacting specimens |

≥20 specimens in total

Including human specimens positive for related human herpesviruses, e.g. EBV, HHV6, VZV

Herpesvirus positive cell cultures may serve as potential substitutes

According to the state of the art

Carry-over |

High CMV DNA positive;

CMV DNA negative

At least five runs with alternating high-positive and negative specimens shall be performed during robustness studies. The virus titres of the high positive specimens shall be representative of high virus titres occurring naturally. | According to the state of the art

Whole system failure rate | CMV DNA low-positive | ≥100 CMV DNA low-positive specimens shall be tested. These specimens shall contain a virus concentration equivalent to three times the 95 % positive cut-off virus concentration. | ≥99% positive